Complejo Asistencial De Zamora Hospital Provincial De Zamora
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At the Complejo Asistencial De Zamora Hospital Provincial De Zamora, researchers are exploring ways to reduce clotting complications in high‑risk patients, particularly focusing on venous thromboembolism prevention and the use of low‑molecular‑weight heparin in oncology settings.
- Prophylaxis of clot formation in metastatic colorectal cancer patients
- Evaluation of anticoagulant strategies during cancer therapy
- Safety monitoring of long‑term anticoagulation
The surgical department collaborates closely with oncology to integrate cardiovascular risk management into comprehensive cancer care.
Digestive System Diseases
Clinical studies at the site aim to improve outcomes for gastrointestinal conditions, ranging from stage IV colon or rectal adenocarcinoma to symptomatic cholelithiasis, and include innovative imaging during laparoscopic cholecystectomy.
- Targeted therapies for advanced colorectal tumors
- Imaging techniques to enhance biliary visualization
- Post‑operative recovery protocols after gallbladder surgery
Multidisciplinary teams work together to streamline surgical pathways and reduce postoperative complications.
Neoplasms
The hospital conducts research aimed at advancing treatment options for malignant tumors, with a particular emphasis on metastatic colorectal cancer and patient‑centered quality of life.
- Combination chemotherapy and targeted agents
- Quality‑of‑life assessments during cancer therapy
- Biomarker discovery for treatment response
Oncology investigators partner with surgical colleagues to evaluate peri‑operative interventions for tumor control.
Nervous System Diseases
Investigations address disorders of the central nervous system, with a strong emphasis on treatment‑resistant schizophrenia and associated cognitive impairment.
- Novel antipsychotic agents for refractory symptoms
- Safety follow‑up after long‑term exposure
- Cognitive function monitoring in chronic schizophrenia
The department’s neuro‑psychiatric expertise supports comprehensive care for patients with severe mental illness.
Behavior and Behavior Mechanisms
Research examines behavioral disturbances in neurodevelopmental and neurodegenerative conditions, seeking better management strategies for irritability associated with autistic disorder and agitation in Alzheimer’s disease.
- Behavioral rating scales for autism
- Intervention trials for agitation in dementia
- Parent‑reported outcomes for irritability
Findings aim to reduce caregiver burden and improve daily functioning for affected individuals.
Mental Disorders
Trials target major mood and psychotic disorders, testing adjunctive therapies to enhance existing treatments for major depressive disorder with anhedonia, schizophrenia, and psychosis associated with Alzheimer’s disease.
- Adjunctive antidepressant strategies for anhedonia
- Antipsychotic augmentation in resistant schizophrenia
- Psychosis mitigation in Alzheimer’s patients
The aim is to broaden therapeutic options and improve symptom control across a spectrum of mental health conditions.
Psychological Phenomena
The focus is on subjective experiences such as agitation associated with Alzheimer’s dementia and psychosis in Alzheimer’s disease, aiming to enhance patient comfort and reduce caregiver stress.
- Non‑pharmacologic approaches to agitation
- Medication safety in elderly with psychosis
- Caregiver training for behavioral management
Researchers evaluate both drug and behavioral interventions to identify the most effective strategies.
General Clinical Research
Beyond disease‑specific studies, the department runs exploratory projects that bridge surgery, psychiatry, and oncology to enhance overall patient care, emphasizing multidisciplinary collaboration.
- Cross‑specialty protocol development
- Health‑outcome metrics across surgical procedures
- Long‑term follow‑up registries
These initiatives support continuous improvement of clinical practice within the hospital.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Intra-Cellular Therapies Inc.3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Intra-Cellular Therapies Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Complejo Asistencial De Zamora Hospital Provincial De Zamora
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder. | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Mar 2023 | Nov 2025 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acp-204 Tartrate | 2 | Unknown | 2024-07-02 | 2024-12-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
